Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Go back to Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
(NASDAQ: KLRS) Delayed: 3.92 -0.15 (3.69%)
Previous Close $4.07    52 Week High
Open $3.93    52 Week Low
Day High $4.19    P/E N/A 
Day Low $3.82    EPS
Volume 137,673